drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody)
drug_description
A fully human IgG1-like bispecific monoclonal antibody targeting EGFR and MET; blocks ligand binding and receptor activation, disrupts EGFR–MET crosstalk, inhibits MAPK/ERK and PI3K/AKT signaling, and may mediate ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
A fully human IgG1-like bispecific monoclonal antibody that binds EGFR and MET on tumor cells, blocking ligand binding and receptor activation, disrupting EGFR–MET crosstalk, and inhibiting downstream MAPK/ERK and PI3K/AKT signaling; its IgG1 Fc may also mediate ADCC.
drug_name
HS-20117 (PM1080)
nct_id_drug_ref
NCT05940116